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Abstract In the present study we have demonstrated that WT1
(Wilms tumor suppressor gene) enhances the expression of
TauT (taurine transporter gene) in human embryonic kidney
293 cells in a dose-dependent manner. TauT promoter activity
was increased ¢ve-fold by cotransfection of a full-length TauT
promoter^reporter construct with WT1. Electrophoretic mobil-
ity shift assays (EMSAs) using nuclear extracts from WT1-
overexpressing 293 cells showed a putative WT1-binding site
in the basal promoter region of TauT, which bound to WT1
in EMSAs. Mutation of this WT1 consensus sequence abolished
binding of WT1. These results demonstrate that TauT may
represent a downstream target gene of WT1 during renal devel-
opment.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Taurine has been shown to be essential for the development
and survival of mammalian cells, particularly cells of cerebel-
lum, retina, and kidney [1^3]. Sturman et al. [2] demonstrated
that the surviving o¡spring of taurine-de¢cient female cats
have a large number of neurological defects, including degen-
eration of retinal pigmented epithelium and ocular tapetum,
delayed cerebellar granule cell division and migration, and
abnormal cerebral cortical development. Recently, Maar et
al. con¢rmed the observations that taurine depletion severely
a¡ects migration of cerebellar granule neurons during early
postnatal development by using cultures of dissociated cere-
bellum of 5- to 6-day-old mice and N2A neuronal cells [4].
They found that taurine depletion by culturing the cells in the
presence of a taurine transport inhibitor, guanidoethane sul-
fonate, resulted in a decreased rate of cell migration, suggest-
ing that normal function of the taurine transporter is required
during brain development.
Recent studies demonstrated that taurine and the taurine
transporter play an important role in kidney development
[1,3]. In the F1 generation of inbred taurine-de¢cient cats,
taurine de¢ciency results in renal malformation with signi¢-
cantly diminished renal size and progressive kidney damage.
Histological examination of these kidneys showed ureteral
dilatation, enlarged glomeruli, proximal tubular £attening
and abnormal di¡erentiation of renal tubular epithelium, es-
pecially in the distal tubule, where taurine has been found to
be in highest concentration in immunohistochemical studies
[3,5]. Consistent with these ¢ndings, Heller-Stilb et al. [1] dem-
onstrated that knockout of TauT (taurine transporter gene)
resulted in severe and progressive retinal degeneration, a small
brain, and shrunken kidneys in a taut3/3 mouse model.
These ¢ndings con¢rm that TauT is required for retinal, brain,
and kidney development.
We have recently shown that the promoter region of TauT
contains an overlapping consensus site for WT1 (Wilms tumor
suppressor gene)/EGR-1 (early growth response gene 1)/Sp1.
It has been demonstrated that WT1 plays a critical role in
kidney development [6]. However, the precise mechanism by
which WT1 exerts its e¡ects during development awaits iden-
ti¢cation of actual target gene(s) that it regulates during renal
development.
2. Experimental procedures
2.1. Construction of the reporter gene
The promoter region of TauT was identi¢ed in previous studies [7],
and a WT1-binding consensus site was found in the TauT promoter
sequence, located at 3160 to 3171. In this study, approximately 1.1
kb of the TauT promoter region DNA (GenBank accession number
AR151716) was used as the template for PCR and the PCR fragment
was cloned into the promoterless luciferase vector pGL3-Basic (Prom-
ega, Madison, WI, USA) to generate the plasmid p963 for use in
transfections and luciferase assays. The conditions used are 30 cycles
of 1 min of denaturation at 94‡C, 1 min of annealing at 58‡C, and
1 min of elongation at 72‡C. The sense primer (5P-GGGGTACCT-
TACTGAAGGTCACACAGC-3P) designed for PCR contained a
unique site for KpnI, and the antisense primer (5P-AAGATCTTGG-
CACGGGAGTTCA-3P) contained a unique site for BgIII. PCR
products were digested with KpnI and BgIII and re-ligated into
KpnI and BgIII sites of pGL3-Basic to generate plasmids containing
segments of the TauT promoter sequence extending from the +48
nucleotide corresponding to the transcriptional start site. The con-
structs were veri¢ed by DNA sequencing. The 5P-progressive deletions
were generated from the p963 plasmid by using sense primers 5P-G-
GTTCTTTGTGTGTCCGAGCTCCTG-3P (p265), 5P-GGGGTACC-
TGTGTGTGGGCGT-3P (p182), 5P-GGGGTACCAGACCCCGCC-
CTA-3P (p-sp1), 5P-GGGGTACCTAGGCCCCGCCCA-3P (p-sp2),
5P-GGGGTACCAGGCCCGGCCAAG-3P (p-sp3), and 5P-GGGGT-
ACCAGCAGGATGGGTG-3P (p-sp4), respectively. The antisense
primer used for these constructs was the same as described above.
The 3P-progressive deletion was generated from p963 by using the
same sense primer for p182 and antisense primers 5P-GGGGCCTG-
GGAGGTCAGCCACG-3P (pd-sp1), 5P-GGGGCCTGGGGAGGG-
GTCTGGGCGGT-3P (pd-sp2), 5P-CCGGGCCTGGGAGGGGCCT-
A-3P (pd-sp3), and 5P-CCGGGCCTGGGCGGGGCCTA-3P (pd-sp4).
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2.2. Cell culture
Human embryonic kidney (293) cells were cultured according to
American Type Culture Collection guidelines. Brie£y, cells were
grown as con£uent monolayers in 10 cm diameter tissue culture plates
in Dulbecco’s modi¢ed Eagle’s medium/F12 medium with 10% fetal
calf serum at 37‡C in the presence of 5% CO2 in a humidi¢ed incu-
bator. Cells were plated 18 h before transfection and fed with fresh
medium 4 h before transfection.
2.3. Stable expression of WT1 in 293 cells
293 cells were transfected with WT1 and CMV neo Bam plasmid
DNA (vector control) by electroporation using a Gene Pulser electro-
porator (Bio-Rad, Hercules, CA, USA). Geniticin (G418, 1 mg/ml,
Clontech, Palo Alto, CA, USA) was used for colony selection. G418-
resistant colonies (293/WT1) were screened by Western blot analysis
for WT1 expression. In order to test the role of wild-type WT1 in
TauT expression, WT1-overexpressing 293 cells were used in this
study.
2.4. Transient transfection
The reporter gene constructs and WT1 expression vectors (a gift
from Dr. John Schuetz at St. Jude Children’s Research Hospital,
Memphis, TN, USA) were introduced into cultured mammalian cells
using cationic liposomes (LipofectAMINE, Life Technologies). Trans-
fection was carried out for 16^18 h, and then cells were washed twice
with phosphate-bu¡ered saline and incubated in fresh medium for 24^
48 h before harvesting. pGL-control, which contains a luciferase gene
driven by the SV40 early region promoter/enhancer, and empty pGL-
Basic vectors were used as positive and negative controls, respectively.
To standardize the transfection e⁄ciency, 0.1 Wg of pRL-CMV vector
(pRL Renilla Luciferase control reporter vector, Promega) was
cotransfected in all experiments. Cells were harvested 48 h after
transfection and lysed in 200 Wl of reporter lysis bu¡er (Promega).
A luciferase assay was performed using a dual-luciferase assay kit
(Promega), and activity was measured with an Optocomp 1 luminom-
eter (MGM Instruments, Inc., Hamden, CT, USA). Promoter activity
(meanRS.D. of four samples in relative light units) of each construct
is represented by relative light output normalized to pRL-CMV con-
trol. Graphs represent typical results of three separate experiments.
The concentration of protein in the cell extracts was determined using
the Bradford method (Bio-Rad, Hercules, CA, USA).
2.5. Northern blot analysis
30 Wg of total RNA was separated in an agarose gel and transferred
to a nylon membrane by overnight capillary blotting in 10USSC
(sodium chloride/sodium citrate bu¡er). The Northern blot was hy-
bridized overnight at 42‡C with a 32P-labeled riboprobe of the taurine
transporter cDNA. The blot was washed successively in standard
decreasing concentrations of SSC/0.1% SDS at 65‡C for 30 min
each and exposed to Kodak ¢lm with one intensifying screen at
380‡C for 24 h.
2.6. Western blot analysis
Cells were lysed in 50 Wl M-PER mammalian protein extraction
reagent (Pierce, Inc., Rockford, IL, USA) supplemented with protease
inhibitors cocktail for use with mammalian cell and tissues extracts
(Sigma, St. Louis, MO, USA). The lysates were cleared by centrifu-
gation at 14 000Ug for 2 min, and the supernatants were transferred
to clean tubes. Equal amounts of protein (50 Wg) were separated by
electrophoresis on a 12% SDS^polyacrylamide gel and transferred to a
nitrocellulose membrane (Millipore, Bedford, MA, USA) using a
semi-dry electrophoretic transfer system (Bio-Rad, Hercules, CA,
USA). Membranes were incubated in 5% non-fat dry milk in Tris
base/sodium chloride (TBS) bu¡er with 0.2% Tween 20 (TBST) at
4‡C overnight. The membranes were incubated with primary antibody
for 1 h at room temperature at the following dilutions: WT1 (180)
(Santa Cruz, CA, USA) 1:2000, and 1:5000 of an a⁄nity-puri¢ed
antibody against the C-terminal peptide sequence of the taurine trans-
porter [8]. Blots were washed with TBST and incubated with horse-
radish peroxidase-linked secondary antibody (Sigma). TauT or WT1
protein was detected using a chemiluminescent detection kit (Pierce,
Inc.).
2.7. Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides corresponding to the putative
WT1-binding site in the TauT promoter region were end-labelled
with polynucleotide kinase using [Q-32P]ATP. Nuclear extracts were
isolated by high salt extraction of nuclei [9]. The binding reactions
were performed by using a gel shift assay system following the man-
ufacturer’s instructions (Promega). Brie£y, the labelled oligonucleoti-
des and nuclear extracts were incubated in gel shift binding bu¡er
[20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250
mM NaCl, 50 mM Tris^HCl (pH 7.5), and 0.25 mg/ml poly (dl^
dC)] on ice for 30 min, and then the DNA^protein complexes were
run on 10% non-denaturing acrylamide TBE gels (Bio-Rad) in 0.5U
TBE bu¡er at 190 V for 45 min. The gel was dried at 70‡C for 30 min
and exposed to Kodak ¢lm with an intensifying screen for 1 h at
380‡C.
2.8. Statistics
All experiments were performed in triplicate. Luciferase assays are
expressed in units of relative light output. The data represent the
meanRS.E.M. of three experiments. Statistical comparisons were
made using one-way ANOVA and Student’s t-test to determine sig-
ni¢cant di¡erences in the means.
3. Results
3.1. TauT is up-regulated by WT1
To study if WT1 regulates TauT expression in 293 cells,
various doses of WT1 were transiently transfected into the
293 cells by electroporation. The transfected cells were con-
 
 
Fig. 1. TauT is up-regulated by WT1. A: Northern blot analysis of
TauT expression in 293 cells transfected with WT1 for 48 h. Lane
1, control; lane 2, 0.5 Wg WT1; lane 3, 1 Wg WT1; lane 4, 5 Wg
WT1; and lane 5, 10 Wg WT1. L-Actin was used as an internal con-
trol for loading. B: Western blot analysis of TauT gene expression
in 293 cells transfected with WT1 (0^10 Wg) for 48 h. Equal
amounts of protein were loaded on an SDS^polyacrylamide gel
(12% acrylamide) and the taurine transporter protein was detected
as described in Section 2. The housekeeping gene L-actin was used
as loading control. The result represented three separate experi-
ments.
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tinually cultured for another 48 h. As shown in Fig. 1A, ex-
pression of TauT was up-regulated by WT1 in a dose-depen-
dent manner. The increase in the amount of WT1 was accom-
panied by enhanced expression of TauT protein (Fig. 1B).
To extend this study, the WT1 was stably transfected into
293 cells and expression of TauT was determined. As shown
in Fig. 2A, overexpression of WT1 increased the transcription
of TauT mRNA by more than two-fold. Western blot analy-
ses show that the expression of WT1 is undetectable in wild-
type 293 cells, whereas a high level of WT1 was found in
WT1-expressing cells, in which expression of TauT protein
was doubled as compared to the control cells transfected
with the empty expression vector (Fig. 2B).
3.2. TauT is transcriptionally activated by WT1
To determine if up-regulation of the TauT gene by WT1
occurs at the transcriptional level, the reporter constructs,
including p265 which contains a putative WT1/EGR-1/Sp1-
binding site from 3160 to 3171 and the indicated constructs
created by progressive deletion as shown in Fig. 3A, were
transiently transfected into 293 cells. Regulation of TauT pro-
moter activity by WT1 was examined. As shown in Fig. 3B,
reporter gene p265, which contains a TG repeat, shows strong
promoter activity that was enhanced ¢ve-fold by WT1. Dele-
tion of the TG repeat repressed basal promoter activity of
TauT, and had no e¡ect on its up-regulation by WT1. Dele-
tion of the WT1/EGR-1/Sp1 site abolished the e¡ect of WT1
on TauT promoter function. Consistent with our previous
study, we have also demonstrated that an Sp1 site is essential
for the basal promoter function of TauT in 293 cells.
To determine if the WT1/EGR-1/Sp1 overlapping site is
su⁄cient for the basal promoter function of TauT and its
regulation by WT1, progressive deletion was carried out
from the 3P-sequence of the TauT promoter region and the
resulting reporter gene constructs were transiently transfected
 
 
Fig. 2. Up-regulation of TauT expression by stable transfection of
WT1 in 293 cells. A: Northern blot analysis was carried out using a
speci¢c RNA probe generated from human taurine transporter
cDNA [12]. Lanes 1 and 2, control 293 cells ; lanes 3 and 4, WT1-
overexpressing 293 cells. B: Western blot analysis of TauT expres-
sion was performed using an antibody against the C-terminal pep-
tide sequence of TauT. Expression of WT1 was detected by a WT1
antibody (WT 180, Santa Cruz Biotechnology, CA, USA). Sample
loading sequence was the same as described in A.
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-151CCAGACCCCGCCCTAGGCCCCGCCCAGGCCCGGCCAAGCTGGTATTTTTC
-101CACCCAGCAGGATGGGTGATGCGGAGAGCTGCCTGTTCAGACAACAGACA
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Fig. 3. WT1/EGR-1/Sp1 consensus site is required for WT1 regula-
tion of TauT promoter activity. A: Schematic representation of
TauT promoter^reporter constructs. B: E¡ect of deletion of the
WT1 site on activation of TauT promoter by WT1 was carried out
in 293 cells. Reporter gene constructs as indicated in A were transi-
ently transfected into 293 cells for 24 h, and then a luciferase assay
was performed as described in Section 2. To control for transfection
e⁄ciency, cells were cotransfected with pRL-CMV vector (0.1 Wg),
luciferase activity was measured in cell lysates by the dual-luciferase
reporter assay system. The promoter activity (meanRS.D. of four
samples) is represented by relative light output normalized to pRL-
CMV control. The graph represents typical results of four separate
experiments.
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into 293 cells. As shown in Fig. 4A,B, deletion of all indicated
Sp1 sites (pd^sp4) did not a¡ect TauT promoter function and
its up-regulation by WT1, as compared to the reporter gene
construct p182. These results suggest that theWT1/EGR-1/Sp1
overlapping site is critical for the basal promoter function of
TauT and its up-regulation by WT1.
3.3. WT1-binding site is necessary for the transcriptional
activation of TauT by WT1
To de¢ne whether WT1 binds to this putative WT1/EGR-1/
Sp1 overlapping site in the TauT promoter, we carried out
EMSAs using the synthetic oligonucleotides corresponding
to this site (Fig. 5A). As shown in Fig. 5B, nuclear extracts
from WT1-overexpressing 293 cells yielded a band (lane 2)
that could be competed out by excess unlabelled probe (lane
3). Control 293 cells did not yield a band (lane 1). Mutation
of the WT1/EGR-1/Sp1 sequence, in which three thymines (T)
were mutated to adenines (A), results in the loss of WT1
binding to this site (lane 5). A polyclonal antibody to WT1
(WT1 180, Santa Cruz, CA, USA) resulted in a super-shifted
band (lane 4), suggesting that WT1 speci¢cally binds to the
putative WT1/EGR-1/Sp1 overlapping site in the TauT pro-
moter region.
4. Discussion
Taurine functions as an osmoregulator and intracellular
calcium £ux regulator and has been found to play an impor-
tant role in kidney development [3]. Heller-Stilb and his co-
workers have demonstrated that mutation of TauT results in
retinal degeneration and diminished renal size [1], suggesting
that TauT per se plays an important role in normal retinal
Fig. 4. Sp1 site is not necessary for WT1 regulation of TauT promoter. A: Schematic representation of TauT promoter^reporter constructs.
B: E¡ect of deletion of the Sp1 sites on activation of TauT promoter by WT1 in 293 cells. Reporter gene constructs as indicated in A were
transiently transfected into 293 cells for 24 h, and then a luciferase assay was performed as described in the legend to Fig. 3.
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and kidney development. We have recently shown that TauT
is a target gene of p53, and that it is negatively regulated by
p53 in renal cells. These ¢ndings strongly support the role of
TauT in renal development, since overexpression of p53 in p53
transgenic mice results in severe renal damage, which is sim-
ilar to the observations made in the taurine-de¢cient cats
[3,10].
In the present study, we show that TauT is likely a target
gene of WT1, which plays a critical role in kidney develop-
ment [6]. First, we demonstrated that expression of TauT was
up-regulated by WT1 in human embryonic 293 renal cells in a
dose-dependent manner. This result was con¢rmed by stable
transfection of WT1 into 293 cells. Secondly, our results
showed that regulation of TauT by WT1 occurred at the tran-
scriptional level, as demonstrated by using a luciferase report-
er gene driven by the TauT promoter. We have also demon-
strated that the WT1/EGR-1/Sp1 overlapping site located at
3160 to 3171 is essential for WT1 regulation. It appears that
the TG repeat, which is located immediately upstream of the
WT1/EGR-1/Sp1 site, is important for the maximum e¡ect of
WT1 on TauT promoter function. Deletion of the TG repeat
represses the basal promoter activity of TauT by 60%.
Thirdly, we showed that WT1 increased TauT transcription
by directly binding to the DNA sequence between 3160 and
3171 of the TauT promoter. Mutation of this consensus site
abolished WT1 binding to the TauT promoter, and abrogated
the e¡ect of WT1 on TauT promoter function.
It has been demonstrated that WT1 plays a critical role in
kidney development. The WT1 gene, located on chromosome
11, band p13, encodes a 50 kDa nuclear transcription factor
that contains four zinc-¢nger DNA-binding domains [13].
Unique WT1 mutations have been demonstrated in individu-
als with Denys-Drash syndrome, which includes intersexual
disorders, nephropathy (mesangial sclerosis), and Wilms tu-
mor. Mutations in the zinc ¢nger domains of WT1-gene were
found in Frasier syndrome, which is de¢ned by the association
of focal and segmental glomerulosclerosis, male pseudoher-
maphroditism, and gonadoblastoma [14]. Expression of the
WT1 gene is restricted during development to mesenchymal
tissues, occurring in speci¢c cells of the collecting system with-
in the kidney, non-germ cell components of the gonads, ute-
rus, spleen, and mesothelium [15]. Knockout of the WT1 gene
results in embryonic lethality in the homozygous state, sec-
ondary to the failure of kidney and gonad development [16].
However, the precise mechanism by which WT1 exerts its
e¡ects during normal development and prevents tumor for-
mation in the kidney awaits identi¢cation of actual target
gene(s) that it regulates during kidney development.
Several lines of evidence suggest that the interaction of p53
and WT1 plays an important role in normal development and
in tumorigenesis [17]. Using in vitro immunoprecipitation and
Western blot analyses, p53 and WT1 proteins were shown to
physically interact in BRK (baby rat kidney) cells [18]. WT1
protein was shown to stabilize p53, modulate its transactiva-
tional properties, and inhibit its ability to induce apoptosis
(programmed cell death) [19].
Taken altogether, our results suggest that TauT is a target
gene of WT1. Regarding the action of p53 on TauT regulation
and the role of the taurine transporter in renal development
[11], we concluded that TauT plays an important role in nor-
mal nephrogenesis. The function of TauT is regulated by WT1
and p53, which control a ¢ne balance between cell prolifera-
tion and apoptosis during renal development.
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